Is Evening Primrose Skin Health Randomized Trial safe?

Updated October 2026

Quick Answer

Evening Primrose Skin Health Randomized Trial has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Conclusion SheVari4 ® significantly improved menopause-specific QOL and endocrine parameters in peri- and post-menopausal women, with a well-established safety profile.

Key Takeaways

  • 01Conclusion SheVari4 ® significantly improved menopause-specific QOL and endocrine parameters in peri- and post-menopausal women, with a well-established safety profile. [Chattopadhyay R (2026)]
  • 02Objective Menopause marks the natural end of reproductive phase of women caused by decline in levels of estrogen, progesterone and other reproductive hormones. [Chattopadhyay R (2026)]
  • 03Asparagus racemosus (Shatavari) is a medicinal herb particularly known to be effective in alleviating women's reproductive health. [Chattopadhyay R (2026)]
  • 04Mastalgia is a common breast complaint in women, particularly those of reproductive age, often leading to significant physical and psychological distress. [Arya A (2025)]
The current Migaku evidence database contains 2 reusable source documents for Evening Primrose Skin Health Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - Conclusion SheVari4 ® significantly improved menopause-specific QOL and endocrine parameters in peri- and post-menopausal women, with a well-established safety profile. [Chattopadhyay R (2026); evidence level 2] - Objective Menopause marks the natural end of reproductive phase of women caused by decline in levels of estrogen, progesterone and other reproductive hormones. [Chattopadhyay R (2026); evidence level 2] - Asparagus racemosus (Shatavari) is a medicinal herb particularly known to be effective in alleviating women's reproductive health. [Chattopadhyay R (2026); evidence level 2] - Mastalgia is a common breast complaint in women, particularly those of reproductive age, often leading to significant physical and psychological distress. [Arya A (2025); evidence level 4] - Therefore, it is of interest to evaluate 100 female patients with mastalgia over an 18-month period, assessing them through clinical examination, ultrasonography (USG), fine needle aspiration cytology (FNAC) and mammography. [Arya A (2025); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. SheVari4<sup>®</sup>, a proprietary root extract from <i>Asparagus racemosus</i>, ameliorates menopausal health: insights from a randomized, double-blind, placebo controlled clinical trial.
  2. Epidemiology of Mastalgia in rural populations: A study from Ujjain, India.